Astrazeneca Ab

Bernard Christophe Barlaam

David Waterson

Howard Tucker

Nicholas John Newcombe

Richard Ducray

Jason Grant Kettle

Patrick Ple

Kurt G Pike

Timothy Piser

Christine Marie Paul Lambert-Van Der Brempt

Benedicte Delouvrie

Cathy Dantzman

Craig Steven Harris

Gilles Ouvry

Andrew Peter Thomas

Robert Hugh Bradbury

Laurent Francois Andre Hennequin

Maurice Raymond Verschoyle Finlay

Robert I Dowell

Kevin Michael Foote

Peter Robert Bernstein

Clifford David Jones

Jean-Jacques Marcel Lohmann

James Jeffrey Folmer

David Berry

Sebastien Louis Degorce

Christopher Thomas Halsall

Gary Peter Tomkinson

Christine Marie Paul Lambert

Gary Patrick Reid

Justin Fairfield Bower

Jon James Gordon Winter

Gary Fairley

Andrew Pape

Paul Warwick

Christine Marie Lambert-Van Der Brempt

Remy Robert Morgentin

Robert Ian Dowell

Christine Lambert

The specification generally relates to compounds of Formula (I): 

Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R, R, R, Rand Rhave any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.

Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein Rand Rhave any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Chemical compounds

The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer. 

Pyridine compounds

The invention concerns chromenone compounds of Formula I; or pharmaceutically-acceptable salts thereof, wherein each of R, R, R, R, R, n and Rhas any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

Chromenone derivatives

The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G, G, G, G, J, Ring A, n and Rhas any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

Pyridine and pyrazine derivatives -083

The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man. 

Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents

The invention concerns quinazoline derivatives of Formula (I), wherein each of R, R, R, Rand a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases. 

Quinazoline derivatives as antiproliferative agents

A quinazoline derivative of the Formula I: 

4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer

A compound of formula (I) where one of A, Aor Ais N, and the others are independently selected from CH or N; ring B is a fused 5 or 6-membered carbocyclic or heterocyclic ring which is optionally substituted as defined in the specification, and R, R, R, R, and n are as defined in the specification. The compounds are inhibitors of EphB4 or EphA2 and therefore may be useful in pharmaceutical compositions for the treatment of conditions such as cancer.

Pyrimidine derivatives for inhibiting Eph receptors

The invention provides compounds of formula in which R, R, Rand Rhave the meanings defined in the specification; processes for the preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.

Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-I)

Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13 

Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)

The invention relates to novel compounds having the general formula: (I) and arc useful as selective ER-&#x3b2; ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis cardiovascular disease, rheumatoid arthritis or prostate cancer.

Selective estrogen receptor-&#x3b2; ligands

A method for treating a disease associated with the estrogen receptor-&#x3b2;, comprising the step of administiering a therapeutically-effective amount of a compound that satifies the equation: K/K&#x3e;25, optionally having general structure (I).

Estrogen receptor-&#x3b2; ligands

Compounds of the formula I useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Growing community of inventors

Reims, France

Bernard Christophe Barlaam